Fulcrum Therapeutics

#BreakingNews. Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD). “Sanofi is a proven leader in developing therapeutics for rare neuromuscular diseases and is the ideal partner to maximize the opportunity and reach of losmapimod outside the U.S.,” said Alex C. Sapir, Fulcrum’s president and chief executive officer. “This deal aligns with our core strategy, allowing Fulcrum to remain focused on preparations for commercialization of losmapimod in the U.S., while leveraging Sanofi’s exceptional global commercial capabilities and established infrastructure in key markets around the world. We are excited about the potential to provide the first approved treatment for FSHD patients, and we look forward to working with Sanofi to bring losmapimod to patients globally.” Learn more from our press release: https://ow.ly/I4jQ50REel8 #FSHD #FSHDawareness #Biotech #FulcrumTherapeutics #healthinnovations #newsalert

A massive shoutout to Improv Asylum for an incredible session at our All Hands meeting! We learned innovative ways to build trust, communicate effectively, and sharpen our listening skills—all while having an absolute blast as a team. Thank you for the unforgettable experience! #FULcrew #WeAreRare

Looking for a career where you can leave an impact? Join our team! We’re hiring for the following positions: - Executive Director/Sr Director, Alliance Management - Senior Manager, Administrative Services - Vice President, Hematology Clinical Development Apply now at fulcrumtx.com/careers. #biotech #careers #WeAreRare

Happy Fourth of July from the FULcrew! 🇺🇸 Wishing you a safe and relaxing holiday. #FourthOfJuly #IndependenceDay #FULcrew

Happy Fourth of July from the FULcrew! 🇺🇸 Wishing you a safe and relaxing holiday. #FourthOfJuly #IndependenceDay #FULcrew

We've been thrilled to welcome some fantastic new team members to the FULcrew in 2024. Together, we're excited to make a meaningful impact! #careers #biotech

Resilience is an all too familiar concept to those living with rare diseases and to those in the LGBTQ community. The stigma faced by both communities is significant, but when combined, it has an even greater impact. Researchers have found that the stigma associated with rare diseases (like stares or unkind comments) are magnified when that person is also LGBTQ. In this Voices of Rare interview, SCD patient advocate Tristan Lee gives us a glimpse of what that stigma is like and how he has overcome it. #voicesofrare #rarediseaseawareness

#Reminder: Today (June 23) at 1:10 pm ET, Jeff Jacobs presents “Losmapimod, a p38 Small Molecule Inhibitor, Selectively Inhibits the DUX4 Program Without Negatively Impacting Myogenesis in FSHD.” Find his presentation and our posters at https://ow.ly/lrUh50Snjbj. #NewDirectionsInScience

#Attn: New Directions Scientific Conference Attendees! Jeff Jacobs, PhD and CSO at Fulcrum Therapeutics will be presenting at 1:10pm ET on Sunday. Stay tuned for links to our posters and his presentation to be shared on Sunday at https://ow.ly/WbZk50Sniwe. #NewDirectionsInScience

We are thrilled to share that a bipartisan resolution was introduced in the US House of Representatives designating June 20, 2024 as World FSHD Day. Rep. Debbie Dingell (D-MI) introduced the resolution with the support of Rep. Mike Kelly (R-PA), both noting the importance of this day for improving awareness and education about FSHD; encouraging accurate and early diagnosis; supporting funding for research and treatment development; and advancing programs that support individuals living with FSHD and their caregivers. Since our founding in 2015, Fulcrum has been driven by a commitment to make a difference for patients with FSHD. Today, we celebrate the hard work of our partners at the FSHD Society and the resilience of the FSHD patient and caregiver community. Learn more here: https://lnkd.in/eXzjgaQ5 #WorldFSHDDay